Literature DB >> 18278834

The Swedish early psoriatic arthritis register-- 2-year followup: a comparison with early rheumatoid arthritis.

Ulla R C Lindqvist1, Gerd-Marie Alenius, Tomas Husmark, Elke Theander, Gunilla Holmström, Per T Larsson.   

Abstract

OBJECTIVE: Patients with symptoms and signs compatible with psoriatic arthritis (PsA), with or without psoriasis, have been documented in the Swedish Early Psoriatic Arthritis (SwePsA) register. Our aim was to find markers for disease progression and to evaluate treatments for PsA using these data.
METHODS: Patients referred to rheumatology outpatient clinics within 2 years of onset were assessed on inclusion and at followup 2 years later. Data collection was performed according to the program for SwePsA, and classification was as described by Moll and Wright and the ClASsification Criteria for Psoriatic ARthritis (CASPAR). Remission was recorded if the patient had no tender or swollen joints and if erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were within the reference range. Patients with early rheumatoid arthritis (RA) recruited from the Swedish Early Rheumatoid Arthritis Register (Ramona) provided comparison data.
RESULTS: One hundred thirty-five patients with PsA according to CASPAR were assessed; 44% were classified as having mono/oligoarthritis and 47% as polyarthritis. Two patients (1%) were in remission initially, and 23 (17%) at followup. Patients with polyarticular disease had the highest inflammatory activity, measured by swollen and tender joint counts, ESR, Health Assessment Questionnaire, and self-assessment by visual analog scale of pain and global disease activity. Dactylitis was associated with radiological findings. Compared with RA patients, they had significantly lower CRP, ESR, and number of swollen joints (p = 0.0003, p = 0.0026, p = 0.0380, respectively) at inclusion, but equal numbers of tender joints and self-assessment of pain and disease activity.
CONCLUSION: About half the patients had polyarthritis and the other half had mono/oligoarthritis at followup after 2 years. Patients with polyarthritis had the highest inflammatory activity. Apart from ESR, CRP, and swollen joint count, there were no significant differences in activity between RA and polyarticular PsA.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18278834

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  23 in total

1.  The burden of psoriatic arthritis: a literature review from a global health systems perspective.

Authors:  Seina Lee; Alan Mendelsohn; Evelyn Sarnes
Journal:  P T       Date:  2010-12

Review 2.  The Epidemiology of Psoriatic Arthritis.

Authors:  Alexis Ogdie; Pamela Weiss
Journal:  Rheum Dis Clin North Am       Date:  2015-09-11       Impact factor: 2.670

Review 3.  Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?

Authors:  Dafna D Gladman; Vinod Chandran
Journal:  Curr Rheumatol Rep       Date:  2011-08       Impact factor: 4.592

4.  Joint count reliability in psoriatic arthritis observational trials--an unreported problem.

Authors:  William Tillett; Gavin Shaddick; Eleanor Korendowych; Corinne S de Vries; Neil McHugh
Journal:  Rheumatology (Oxford)       Date:  2012-05-04       Impact factor: 7.580

Review 5.  [Choosing wisely recommendations in rheumatology : One year after their first publication].

Authors:  E Märker-Hermann; A J Voormann
Journal:  Internist (Berl)       Date:  2017-06       Impact factor: 0.743

6.  Which Psoriasis Patients Develop Psoriatic Arthritis?

Authors:  Kristine Busse; Wilson Liao
Journal:  Psoriasis Forum       Date:  2010

Review 7.  Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies.

Authors:  Roberta Ara; John Brazier; Tracey Young
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

Review 8.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Authors:  Angela McArdle; Stephen Pennington; Oliver FitzGerald
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

9.  Remission in psoriatic arthritis.

Authors:  Kurt de Vlam; Rik J U Lories
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

10.  Psoriatic arthritis: pharmacoeconomic considerations.

Authors:  Ignazio Olivieri; Lorenzo Giovanni Mantovani; Salvatore D'Angelo; Angela Padula; Simona de Portu
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.